Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Low-dose prasugrel preserves efficacy but lowers bleeding in elderly

Publish date:: July 23, 2020

Key clinical point: In low-weight and elderly acute coronary syndrome patients, low-dose prasugrel appears preferable to ticagrelor.

Major finding: Both the risk of ischemic events (hazard ratio, 0.82) and bleeding (HR, 0.72) events were numerically lower on low-dose prasugrel than ticagrelor.

Data Source: Prespecified substudy of the phase 4 randomized ISAR-REACT 5 trial.

Disclosures: The senior author, Dr. Kastrati, reported no potential conflicts of interest relevant to this study.

Citation:

Menichelli M et al. Ann Intern Med. 2020 Jul 21. doi: 10.7326/M20-1806.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Thrombosis

DOACs look safe in elective endoscopic procedures,

Lusutrombopag found safe, effective for severe thrombocytopenia in patients with hepatocellular carcinoma,

HOME-PE trial clarifies which pulmonary embolism patients to treat at home,

Aspirin may accelerate cancer progression in older adults,

Low-dose prasugrel preserves efficacy but lowers bleeding in elderly,